ESMO/X
Dec 13, 2024, 16:16
ESMO – Neoadjuvant immunotherapy sets a new standard in stage III melanoma
ESMO shared on LinkedIn:
“More than 40% of patients with resectable stage III melanoma experience disease recurrence within the first few years after initial treatment. The lack of overall survival (OS) benefit with adjuvant immune checkpoint inhibitors (ICIs) has led researchers to explore different approaches.
Recent advancements in Melanoma Treatment, especially with neoadjuvant ICIs, have opened new avenues for improving patient outcomes. Future research will focus on Personalised Plans for individual patients and enhancing our ability to predict both response and toxicities.
Read the opinion piece by Prof Dr Christian Blank in the ESMO Daily Reporter on the occasion of his keynote lecture at ESMOImmuno24. ”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 13, 2024, 17:01
Dec 13, 2024, 16:57
Dec 13, 2024, 16:55
Dec 13, 2024, 16:45
Dec 13, 2024, 16:16
Dec 13, 2024, 16:10